Evaluation of Near-infrared Fluorescence-conjugated Peptides for Visualization of Human Epidermal Receptor 2-overexpressed Gastric Cancer
Kyoungyun Jeong, Seong‐Ho Kong, Seong-Woo Bae, Cho Rong Park, Felix Berlth, Jae Hwan Shin, Yun‐Sang Lee, Hyewon Youn, Eunhee Koo, Yun‐Suhk Suh, Do Joong Park, Hyuk‐Joon Lee, Han‐Kwang Yang
Abstract
PURPOSE: A near-infrared (NIR) fluorescence imaging is a promising tool for cancer-specific image guided surgery. Human epidermal receptor 2 (HER2) is one of the candidate markers for gastric cancer. In this study, we aimed to synthesize HER2-specific NIR fluorescence probes and evaluate their applicability in cancer-specific image-guided surgeries using an animal model. MATERIALS AND METHODS: An NIR dye emitting light at 800 nm (IRDye800CW; Li-COR) was conjugated to trastuzumab and an HER2-specific affibody using a click mechanism. HER2 affinity was assessed using surface plasmon resonance. Gastric cancer cell lines (NCI-N87 and SNU-601) were subcutaneously implanted into female BALB/c nu (6-8 weeks old) mice. After intravenous injection of the probes, biodistribution and fluorescence signal intensity were measured using Lumina II (Perkin Elmer) and a laparoscopic NIR camera (InTheSmart). RESULTS: =4.71 nM); however, the signal was not identified in the tumor, probably owing to rapid renal clearance. CONCLUSIONS: Trastuzumab-IRDye800CW may be used as a potential NIR probe that can be injected 2-3 days before surgery to obtain high HER2-specific signal and contrast. Affibody-based NIR probes may require modifications to enhance mobilization to the tumor site.